Ablynx
Technologiepark 4
Ghent
Zwijnaarde
9052
Tel: 32-0-9-261-06-32
Fax: 32-0-9-261-06-28
Website: http://www.ablynx.com/
Email: info@ablynx.com
282 articles about Ablynx
-
LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company
7/15/2021
LabGenius, a pioneer in the use of machine learning for protein engineering, announced the signing of a multi-year research collaboration with Ablynx, a Sanofi company.
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
The U.S. Food and Drug Administration approved the first treatment for acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi’s Cablivi was given the greenlight and will become a cornerstone of the company’s new rare blood disorders franchise.
-
Pharm-Olam Conducts Pivotal Orphan Disease Trial, Leads to First Therapeutic Approved for the Treatment for Acquired Thrombotic Thrombocytopenic Purpura
10/30/2018
Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.
-
NIH Awards Grant to Battle Sepsis to San Diego's Allele Biotechnology and Pharmaceuticals
10/15/2018
The National Institute of General Medical Sciences, part of the National Institutes of Health, awarded Allele Biotechnology and Pharmaceuticals a Small Business Innovative Research grant to develop therapies for sepsis. -
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.
-
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, Or...
-
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
-
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
-
Ablynx Completes Patient Recruitment in the Phase IIb Respire Study of Its Inhaled Anti-RSV Nanobody ALX-0171
4/30/2018
Ablynx announced that it has successfully completed patient recruitment in the Phase IIb RESPIRE dose-ranging efficacy study of ALX- 0171, the Company’s novel inhaled drug candidate to treat respiratory syncytial virus (RSV) infections.
-
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.
-
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
-
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
-
Ablynx Announces Board Changes - Feb. 7, 2018
2/7/2018
Dr Bo Jesper Hansen has decided to resign from the Board of Directors with immediate effect for personal reasons.
-
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
-
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
-
Ablynx Appoints Dr. Robert Friesen as CSO
1/24/2018
Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations.